Ryman Healthcare’s FY26 retirement living sales hit 1,410 ORAs, aligning with guidance despite a Q4 dip in new sales. The company reports robust aged care occupancy and expects free cash flow near NZD 180 million.
- FY26 total ORA sales reach 1,410, within market guidance
- Q4 sales up 10% year-on-year but down from prior quarter due to fewer internal transfers
- Aged care bed occupancy steady at 96.1% in Q4
- Development completions total 330 units, matching guidance
- Free cash flow forecast around NZD 180 million with disciplined capital management
Sales Performance Reflects Market Expectations
Ryman Healthcare (NZX:RYM) closed FY26 with total retirement living occupation right agreement (ORA) sales of 1,410 units, comfortably within its previously stated guidance range of 1,300 to 1,400. The fourth quarter saw 331 ORA sales, including 81 new sales and 250 resales, marking a 10% increase compared to Q4 FY25 but a decline from the prior quarter, primarily due to fewer internal transfers.
New sales of independent units eased as anticipated, reflecting a slowdown in new unit completions, while serviced apartment sales remained strong, driven by activity at villages including Kevin Hickman, Keith Park, and Bert Newton. Keith Park’s February stage completion contributed to FY26’s total development completions of 330 units and beds, aligning with market expectations.
Stable Occupancy and Growing Care Demand
Demand for Ryman’s aged care services remains robust, with mature care centre occupancy steady at 96.1% in Q4, consistent with the previous quarter. The company highlighted that four out of five care centres opened in the last two years have surpassed 80% occupancy, indicating strong uptake ahead of projections.
Ryman’s integrated village model continues to offer residents a continuum of care, combining independent living with assisted living and aged care services, which supports resident retention and satisfaction.
Financial Discipline Amid Economic Uncertainties
CEO Naomi James pointed to positive trends in lead indicators, noting that net sales applications have exceeded turnover for the first time since contract term changes in late 2024. The new Deferred Management Fee (DMF) of 30% has gained broad acceptance, underpinning Ryman’s targeted sales and marketing strategies.
While the Middle East conflict has not yet impacted settled sales or operations, Ryman is monitoring potential effects on cost inflation, interest rates, and residential property markets. The company’s cautious approach is evident in its reduced development activity, with only two sites under active construction at year-end, mitigating exposure to construction cost inflation.
Ryman expects free cash flow for FY26 to be approximately NZD 180 million, driven by strong cash flow in the second half. Net interest-bearing debt stood at NZD 1.57 billion as of 31 March 2026, with over 75% of drawn debt on fixed interest rates, reflecting prudent capital management.
Looking Ahead to FY26 Results
Ryman will release its audited FY26 results on 26 May 2026, which will provide further clarity on financial performance and strategic direction. Investors will be keen to see how the company navigates ongoing economic uncertainties and whether its integrated care model continues to drive growth and occupancy.
Given the company’s disciplined approach to development and capital, alongside steady demand for both retirement living and aged care, Ryman appears well-positioned but will need to remain vigilant to external pressures.
This update follows Ryman’s earlier half-year guidance and development milestones, reinforcing the company’s steady execution in a complex market environment.
Bottom Line?
Ryman’s FY26 sales and occupancy stability bolster confidence, but economic headwinds warrant close monitoring as FY27 unfolds.
Questions in the middle?
- Will Ryman’s integrated care model sustain demand amid rising economic pressures?
- How might construction cost inflation and interest rate changes affect Ryman’s development pipeline?
- Can the new Deferred Management Fee continue to support sales momentum in a competitive market?